PubMed

Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Parikh CR, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Irbesartan Diabetic Nephropathy Trial. Collaborative Study Group.

Ann Intern Med. 2003 Apr 1;138(7):542-9.PMID: 12667024 [PubMed - indexed for MEDLINE]Related articlesFree article

Treatment of diabetic nephropathy with angiotensin II receptor antagonist.

Lewis EJ, Lewis JB.

Clin Exp Nephrol. 2003 Mar;7(1):1-8. Review.PMID: 14586737 [PubMed - indexed for MEDLINE]Related articles

The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group.

Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, Ritz E, Lewis EJ.

Nephrol Dial Transplant. 2000 Apr;15(4):487-97.PMID: 10727543 [PubMed - indexed for MEDLINE]Related articlesFree article

Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I; Collaborative Study Group.

N Engl J Med. 2001 Sep 20;345(12):851-60.PMID: 11565517 [PubMed - indexed for MEDLINE]Related articlesFree article

A clinical trial in type 2 diabetic nephropathy.

Lewis EJ, Hunsicker LG, Rodby RA; Collaborative Study Group.

Am J Kidney Dis. 2001 Oct;38(4 Suppl 1):S191-4.PMID: 11576953 [PubMed - indexed for MEDLINE]Related articles

Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.

Busch M, Franke S, Wolf G, Rohde RD, Stein G; Collaborative Study Group.

Nephron Clin Pract. 2008;108(4):c291-7. Epub 2008 Apr 24.PMID: 18434751 [PubMed - indexed for MEDLINE]Related articles

Irbesartan: a review of its use in hypertension and in the management of diabetic nephropathy.

Croom KF, Curran MP, Goa KL, Perry CM.

Drugs. 2004;64(9):999-1028. Review.PMID: 15101793 [PubMed - indexed for MEDLINE]Related articles

[Health economic consequences of the use of irbesartan in patients in Germany with type 2 diabetes, nephropathy and hypertension]

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Ritz E.

Dtsch Med Wochenschr. 2004 Jan 2;129(1-2):13-8. German. PMID: 14703575 [PubMed - indexed for MEDLINE]Related articles

Summaries for patients. Effects of blood pressure drugs in patients with diabetes and kidney disease.

[No authors listed]

Ann Intern Med. 2003 Apr 1;138(7):I43. No abstract available. PMID: 12667050 [PubMed - indexed for MEDLINE]Related articlesFree article

[Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]

Frei A, Palmer AJ, Burnier M, Hess B.

Praxis (Bern 1994). 2006 Mar 15;95(11):401-8. German. PMID: 16570646 [PubMed - indexed for MEDLINE]Related articles

The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group.

N Engl J Med. 2001 Sep 20;345(12):870-8.PMID: 11565519 [PubMed - indexed for MEDLINE]Related articlesFree article

Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: clinical implications and limitations.

Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr, Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ.

J Am Soc Nephrol. 2005 Oct;16(10):3027-37. Epub 2005 Aug 24.PMID: 16120823 [PubMed - indexed for MEDLINE]Related articlesFree article

Cost-effectiveness of early irbesartan treatment versus control (standard antihypertensive medications excluding ACE inhibitors, other angiotensin-2 receptor antagonists, and dihydropyridine calcium channel blockers) or late irbesartan treatment in patients with type 2 diabetes, hypertension, and renal disease.

Palmer AJ, Annemans L, Roze S, Lamotte M, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH.

Diabetes Care. 2004 Aug;27(8):1897-903.PMID: 15277414 [PubMed - indexed for MEDLINE]Related articlesFree article

An economic evaluation of irbesartan in the treatment of patients with type 2 diabetes, hypertension and nephropathy: cost-effectiveness of Irbesartan in Diabetic Nephropathy Trial (IDNT) in the Belgian and French settings.

Palmer AJ, Annemans L, Roze S, Lamotte M, Rodby RA, Cordonnier DJ.

Nephrol Dial Transplant. 2003 Oct;18(10):2059-66.PMID: 13679481 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S; RENAAL Study Investigators.

N Engl J Med. 2001 Sep 20;345(12):861-9.PMID: 11565518 [PubMed - indexed for MEDLINE]Related articlesFree article

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial.

JAMA. 2002 Dec 18;288(23):2981-97. Erratum in: JAMA 2003 Jan 8;289(2):178. JAMA. 2004 May 12;291(18):2196. PMID: 12479763 [PubMed - indexed for MEDLINE]Related articlesFree article

[Effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes]

Parving HH, Lehnert H, Brøchner-Mortensen J, Gomis R, Andersen S, Arner P.

Ugeskr Laeger. 2001 Oct 1;163(40):5519-24. Danish. PMID: 11601118 [PubMed - indexed for MEDLINE]Related articles

A French cost-consequence analysis of the renoprotective benefits of irbesartan in patients with type 2 diabetes and hypertension.

Palmer AJ, Valentine WJ, Tucker DM, Ray JA, Roze S, Annemans L, Lapuerta P, Chen R, Gabriel S, Carita P, Rodby RA, de Zeeuw D, Parving HH, Laville M.

Curr Med Res Opin. 2006 Nov;22(11):2095-100.PMID: 17076969 [PubMed - indexed for MEDLINE]Related articles

Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis.

Palmer AJ, Valentine WJ, Ray JA.

Int J Clin Pract. 2007 Oct;61(10):1626-33. Review.PMID: 17877649 [PubMed - indexed for MEDLINE]Related articles

Health economic implications of irbesartan plus conventional antihypertensive medications versus conventional blood pressure control alone in patients with type 2 diabetes, hypertension, and renal disease in Switzerland.

Palmer AJ, Roze S, Valentine WJ, Ray JA, Frei A, Burnier M, Hess B, Spinas GA, Brändle M.

Swiss Med Wkly. 2006 May 27;136(21-22):346-52.PMID: 16779715 [PubMed - indexed for MEDLINE]Related articlesFree article